Although these findings raise the level of caution required for the use of statin-PPARα agonist combinations, statin-PPARα agonist studies including the ACCORD-LIPID trial using fenofibrate and simvastatin [34] and the FIRST trial using fenofibric acid and atorvastatin [35] have shown no increase of rhabdomyolysis. This evidence concerns the gene PPARA and rhabdomyolysis.